NOTE 1 - BASIS OF PRESENTATION: NOTE 9 - NOTE PAYABLE (Details) - Sangui BioTech GmbH	12 Months Ended
Jun. 30, 2020
Equity Method Investment, Ownership Percentage	90.00%
Equity Method Investment, Additional Information	Effective from June 18, 2018 Sangui BioTech GmbH together with Sastomed GmbH founded Sangui Know-How- und Patentverwertungsgesellschaft mbH & Co. KG (“Sangui KG”). Sangui KG is a limited partnership, with Sangui BioTech GmbH as the general partner (owing 99.8%) and Sastomed GmbH as a limited partner (owning 0.2%).

This serves as a place to record data that is not required by accounting literature but is useful for readers of the financial statements as it relates to the details of an equity method investment in common stock. Such information may include the amount of change for a change in ownership (equity) percentage in a given period and the amount and type of the consideration given or received in relation to the change in ownership.

No definition available.

Name:	us-gaap_EquityMethodInvestmentAdditionalInformation
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration